Intangible Assets, Net (Anchen, QOL Medical, BioAlliance, Glenmark, Monosol, Trademark) (Narrative1) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended							3 Months Ended				3 Months Ended			1 Months Ended			12 Months Ended		1 Months Ended		12 Months Ended		12 Months Ended
	Dec. 31, 2011 years	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2011 BioAlliance Licensing Agreement [Member] employees	Dec. 31, 2011 Developed Products Acquired In Anchen Acquisition [Member]	Dec. 31, 2011 In-Process Research And Development Acquired In Anchen Acquisition [Member]	Dec. 31, 2011 Covenant Not-To-Compete Acquired In Anchen Acquisition [Member]	Jun. 30, 2010 BioAlliance Licensing Agreement [Member]	Dec. 31, 2010 BioAlliance Licensing Agreement [Member]	Dec. 31, 2011 Developed Products Acquired In Anchen Acquisition [Member]	Dec. 31, 2011 Synthon Pharmaceuticals, Inc. Asset Purchase Agreement [Member]	Jun. 27, 2009 QOL Medical, LLC Asset Purchase Agreement [Member]	Dec. 31, 2011 QOL Medical, LLC Asset Purchase Agreement [Member]	Dec. 31, 2010 QOL Medical, LLC Asset Purchase Agreement [Member]	May 31, 2010 Glenmark Generics Limited And Glenmark Generics, Inc. USA Licensing Agreement [Member]	Dec. 31, 2011 Glenmark Generics Limited And Glenmark Generics, Inc. USA Licensing Agreement [Member]	Dec. 31, 2010 Glenmark Generics Limited And Glenmark Generics, Inc. USA Licensing Agreement [Member]	Dec. 31, 2011 MonoSol Rx Licensing Agreement [Member] employees	Dec. 31, 2010 MonoSol Rx Licensing Agreement [Member]	Jul. 31, 2005 Trademark Licensed From Bristol-Myers Squibb Company [Member]	Aug. 31, 2003 Trademark Licensed From Bristol-Myers Squibb Company [Member]	Dec. 31, 2011 Trademark Licensed From Bristol-Myers Squibb Company [Member]	Dec. 31, 2010 Trademark Licensed From Bristol-Myers Squibb Company [Member]	Dec. 31, 2011 In-Process Research And Development Acquired In Anchen Acquisition [Member]	Dec. 31, 2011 Covenant Not-To-Compete Acquired In Anchen Acquisition [Member]
Intangible Assets [Line Items]
Estimated useful life of the intangible assets, minimum, years	3
Estimated useful life of the intangible assets, maximum, years	15
Cash paid to acquire rights	$ 34,450	$ 42,200	$ 1,000					$ 20,000,000				$ 54,500,000
Amortization period	2											12										2		9	3
Payments made under license agreements															15,000
Number of days of marketing exclusivity															180
Payments to MonoSol Rx approval milestone	4,000
Payments to MonoSol Rx pre-launch milestone	2,000
Total number of reduction in workforce, in people				90														90
Payment made as per new product development agreement																					5,000
Additional milestone payment as per the license agreement																				5,000
Common stock shares issued	39,677,291	38,872,663
Proceeds from issuance of common stock	333	354	238
Deferred tax liability	48,814	12,703
Intangible assets, net	$ 311,669	$ 95,467			$ 83,550	$ 126,700	$ 8,542		$ 19,441	$ 83,550	$ 9,600		$ 42,181	$ 46,741		$ 15,000	$ 15,000		$ 5,875			$ 852	$ 2,567	$ 126,700	$ 8,542
Useful life of intangible assets	3